These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 23343178)
41. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients. Ghiuzeli CM; Stýblo M; Saunders J; Calabro A; Budman D; Allen S; Devoe C; Dhingra R Leuk Lymphoma; 2022 Mar; 63(3):653-663. PubMed ID: 34689693 [TBL] [Abstract][Full Text] [Related]
42. [Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia]. Wang J; Huang JB; Liu ZL; Zhang BH; Xu HG; Xue HM; Chen C Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1605-1610. PubMed ID: 29262883 [TBL] [Abstract][Full Text] [Related]
43. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Au WY; Tam S; Fong BM; Kwong YL Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490 [No Abstract] [Full Text] [Related]
44. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Au WY; Tam S; Fong BM; Kwong YL Blood; 2008 Nov; 112(9):3587-90. PubMed ID: 18703707 [TBL] [Abstract][Full Text] [Related]
45. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230 [TBL] [Abstract][Full Text] [Related]
46. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia]. Lengfelder E; Schultheis B; Büchner T; Hehlmann R Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223 [No Abstract] [Full Text] [Related]
47. Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment. Chen B; Cao F; Lu X; Shen S; Zhou J; Le XC Talanta; 2018 Jul; 184():446-451. PubMed ID: 29674067 [TBL] [Abstract][Full Text] [Related]
48. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811 [TBL] [Abstract][Full Text] [Related]
49. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Ebinger M; Schwarze CP; Feuchtinger T; Scheel-Walter HG; Lang P; Hildenbrand S; Gessler P; Handgretinger R Pediatr Hematol Oncol; 2011 May; 28(4):334-7. PubMed ID: 21345080 [TBL] [Abstract][Full Text] [Related]
50. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Gao C; Hu S; Guo M; Hai X; Zhou J Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392 [TBL] [Abstract][Full Text] [Related]
51. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392 [TBL] [Abstract][Full Text] [Related]
52. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Quezada G; Kopp L; Estey E; Wells RJ Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388 [TBL] [Abstract][Full Text] [Related]
53. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444 [TBL] [Abstract][Full Text] [Related]
54. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Mayorga J; Richardson-Hardin C; Dicke KA Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466 [TBL] [Abstract][Full Text] [Related]
55. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
56. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
57. [Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia]. Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen L Zhonghua Xue Ye Xue Za Zhi; 1997 May; 18(5):250-3. PubMed ID: 15622757 [TBL] [Abstract][Full Text] [Related]
58. Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients. Wu M; Pang C; Lu S; Hostetter TH; Hai X Environ Toxicol Pharmacol; 2023 Jun; 100():104142. PubMed ID: 37146668 [TBL] [Abstract][Full Text] [Related]
59. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. Wang QQ; Hua HY; Naranmandura H; Zhu HH Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440 [TBL] [Abstract][Full Text] [Related]
60. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]